Skip to main content

Differenzialtherapie der koronaren Herzkrankheit

Differential therapy in coronary heart disease

Herz volume 39, pages 178–185 (2014)Cite this article

Zusammenfassung

Die heute vorhandenen Therapieoptionen der koronaren Herzkrankheit (KHK) erfordern ein differenziertes, auf den einzelnen Patienten zugeschnittenes, therapeutisches Vorgehen. Grundlage der KHK-Therapie sind Lifestyle-Modifikationen, die je nach individuellem Risikoprofil des Patienten gezielte Schwerpunkte setzen. Die pharmakologische Therapie der KHK hat das Ziel, präventiv Sekundärereignisse zu verhindern (Thrombozytenaggregationshemmer, Statine) und abhängig vom Ausmaß der Beschwerden antianginös wirksam zu sein (kurzwirksame Nitrate, Betablocker, Kalziumantagonisten, ggf. Ivabradin, Ranolazin). Während bei akuten Koronarsyndromen eine umgehende Koronarrevaskularisation erforderlich ist, ist die Entscheidung zur Revaskularisation bei stabiler KHK von der Symptomatik, einer Ischämie-/Vitalitätsdiagnostik sowie ergänzenden invasiven Verfahren (fraktionelle Flussreserve, intravaskulärer Ultraschall) abhängig. Die Differenzialindikation perkutane Koronarintervention (PCI) versus aortokoronare Bypass-Operation orientiert sich insbesondere an Koronarstatus (SYNTAX-Score), Allgemeinzustand und Willen des Patienten. Die internationalen Leitlinien betonen dabei die Rolle einer interdisziplinären Therapieentscheidung im „Heart Team“. Insgesamt stellt die Differenzialtherapie der KHK heute ein herausforderndes Gebiet der Patientenversorgung dar, auf dem zukünftig noch viele weitere Entwicklungen zu erwarten sind.

Abstract

The various contemporary therapeutic options for coronary artery disease (CAD) require differentiated, individualized treatment strategies. The foundations of CAD therapy are lifestyle modifications targeted on the individual risk profile of the patients. Pharmacological therapy of CAD should prevent secondary coronary events (e.g. platelet aggregation inhibitors and statins) and reduce angina in symptomatic patients (e.g. short-acting nitrates, beta blockers, calcium channel blockers and if necessary ivabradine and ranolazine). Revascularization therapy has to be performed promptly in patients with acute coronary syndromes; however, in patients with stable CAD the decision to perform revascularization therapy has to consider symptoms, detection of ischemia and if appropriate intracoronary assessment of hemodynamic relevance of an intermediate stenosis (fractional flow reserve). The differential indications of percutaneous coronary intervention compared to coronary artery bypass grafting depend on the severity of coronary artery disease and the morphology (SYNTAX score), comorbidities and the will of the individual patient. The international guidelines emphasize the value of an interdisciplinary treatment decision in a “heart team”. In summary, differential therapy of CAD has become challenging in the current clinical practice; future developments will probably further improve individualized strategies to treat patients with CAD.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Statistisches Bundesamt (2012) Todesursachen in Deutschland 2012, Fachserie 12, Reihe 4. http://www.destatis.de

  2. Perk J, De Backer G, Gohlke H et al (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33(13):1635–1701

    PubMed  Article  CAS  Google Scholar 

  3. Critchley J, Capewell S (2004) Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev (1):CD003041

    Google Scholar 

  4. Montalescot G, Sechtem U, Achenbach S et al (2013) ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34:2949–3003

    PubMed  Article  Google Scholar 

  5. Meyers DG, Neuberger JS, He J (2009) Cardiovascular effect of bans on smoking in public places: a systematic review and meta-analysis. J Am Coll Cardiol 54(14):1249–1255

    PubMed  Article  Google Scholar 

  6. Schmucker J, Wienbergen H, Seide S et al (2013) Smoking ban in public areas is associated with a reduced incidence of hospital admissions due to ST-elevation myocardial infarctions in non-smokers. Results from the BREMEN STEMI REGISTRY. Eur J Prev Cardiol [Epub ahead of print]

  7. Piepoli MF, Corra U, Benzer W et al (2010) Secondary prevention through cardiac rehabilitation: physical activity counselling and exercise training: key components of the position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur Heart J 31(16):1967–1974

    PubMed  Article  Google Scholar 

  8. Hambrecht R, Wolf A, Gielen S et al (2000) Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 342(7):454–460

    PubMed  Article  CAS  Google Scholar 

  9. Hambrecht R, Walther C, Moebius-Winkler S et al (2004) Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation 109(11):1371–1378

    PubMed  Article  Google Scholar 

  10. Heran BS, Chen JM, Ebrahim S et al (2011) Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev (7):CD001800

    Google Scholar 

  11. Lorgeril M de, Salen P, Martin JL et al (1999) Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 99(6):779–785

    PubMed  Article  Google Scholar 

  12. Estruch R, Ros E, Salas-Salvado J et al (2013) Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368(14):1279–1290

    PubMed  Article  CAS  Google Scholar 

  13. Yusuf S, Zhao F, Mehta SR et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494–502

    PubMed  Article  CAS  Google Scholar 

  14. Steg PG, James SK, Atar D et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33(20):2569–2619

    PubMed  Article  CAS  Google Scholar 

  15. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001–2015

    PubMed  Article  CAS  Google Scholar 

  16. Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045–1057

    PubMed  Article  CAS  Google Scholar 

  17. Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 32(23):2999–3054

    PubMed  Article  Google Scholar 

  18. LaRosa JC, Grundy SM, Waters DD et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352(14):1425–1435

    PubMed  Article  CAS  Google Scholar 

  19. Nissen SE, Nicholls SJ, Sipahi I et al (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295(13):1556–1565

    PubMed  Article  CAS  Google Scholar 

  20. Pitt B, Waters D, Brown WV et al (1999) Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 341(2):70–76

    PubMed  Article  CAS  Google Scholar 

  21. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670–1681

    Article  CAS  Google Scholar 

  22. Patel MR, Peterson ED, Dai D et al (2010) Low diagnostic yield of elective coronary angiography. N Engl J Med 362(10):886–895

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  23. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2013) Nationale VersorgungsLeitlinie Chronische KHK, 2. Aufl. Version 1. http://www.versorgungsleitlinien.de

  24. Hambrecht R, Berra K, Calfas KJ (2013) Cardiology patient page. Managing your angina symptoms with nitroglycerin: what about exercise? Circulation 127(22):e642–e645

    PubMed  Article  Google Scholar 

  25. Muenzel T, Daiber A, Gori T (2011) Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 123(19):2132–2144

    Article  Google Scholar 

  26. Muenzel T, Gori T (2013) Nitrate therapy and nitrate tolerance in patients with coronary artery disease. Curr Opin Pharmacol 13(2):251–259

    Article  CAS  Google Scholar 

  27. Thomas GR, DiFabio JM, Gori T et al (2007) Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol 49(12):1289–1295

    PubMed  Article  CAS  Google Scholar 

  28. Yusuf S, Wittes J, Friedman L (1988) Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 260(14):2088–2093

    PubMed  Article  CAS  Google Scholar 

  29. Bangalore S, Steg G, Deedwania P et al (2012) Beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308(13):1340–1349

    PubMed  Article  CAS  Google Scholar 

  30. Bangalore S, Parkar S, Messerli FH (2009) Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med 122(4):356–365

    PubMed  Article  CAS  Google Scholar 

  31. Reil JC, Boehm M (2008) BEAUTIFUL results – the slower, the better? Lancet 372(9641):779–780

    PubMed  Article  Google Scholar 

  32. Tardif JC, Ford I, Tendera M et al (2005) Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26(23):2529–2536

    PubMed  Article  CAS  Google Scholar 

  33. Tardif JC, Ponikowski P, Kahan T (2009) Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 30(5):540–548

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  34. Fox K, Ford I, Steg P et al (2009) Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 30(19):2337–2345

    PubMed  Article  CAS  Google Scholar 

  35. Hasenfuss G, Maier LS (2008) Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol 97(4):222–226

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  36. Chaitman BR, Pepine CJ, Parker JO et al (2004) Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291(3):309–316

    PubMed  Article  CAS  Google Scholar 

  37. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al (2007) Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 297(16):1775–1783

    PubMed  Article  CAS  Google Scholar 

  38. Morrow DA, Scirica BM, Chaitman BR et al (2009) Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 119(15):2032–2039

    PubMed  Article  CAS  Google Scholar 

  39. Timmis AD, Chaitman BR, Crager M (2006) Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 27(1):42–48

    PubMed  Article  CAS  Google Scholar 

  40. Kosiborod M, Arnold SV, Spertus JA et al (2013) Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol 61(20):2038–2045

    PubMed  Article  CAS  Google Scholar 

  41. RITA-2 trial participants (1997) Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 350(9076):461–468

    Google Scholar 

  42. Boden WE, O’Rourke RA, Teo KK et al (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356(15):1503–1516

    PubMed  Article  CAS  Google Scholar 

  43. Shaw LJ, Berman DS, Maron DJ et al (2008) Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117(10):1283–1291

    PubMed  Article  Google Scholar 

  44. BARI 2D Study Group, Frye RL, August P et al (2009) A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360(24):2503–2515

    Article  Google Scholar 

  45. Pfisterer ME, Zellweger MJ, Gersh BJ (2010) Management of stable coronary artery disease. Lancet 375(9716):763–772

    PubMed  Article  CAS  Google Scholar 

  46. Mecklai A, Bangalore S, Hochman J (2013) How and when to decide on revascularization in stable ischemic heart disease. Curr Treat Options Cardiovasc Med 15(1):79–92

    PubMed  Article  Google Scholar 

  47. De Bruyne B, Pijls NH, Kalesan B et al (2012) Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367(11):991–1001

    Article  CAS  Google Scholar 

  48. Jasti V, Ivan E, Yalamanchili V et al (2004) Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis. Circulation 110(18):2831–2836

    PubMed  Article  Google Scholar 

  49. Barlis P, Schmitt JM (2009) Current and future developments in intracoronary optical coherence tomography imaging. EuroIntervention 4(4):529–533

    PubMed  Article  Google Scholar 

  50. Wijns W, Kolh P, Danchin N et al (2010) Guidelines on myocardial revascularization. Eur Heart J 31(20):2501–2555

    PubMed  Article  Google Scholar 

  51. Serruys PW, Morice MC, Kappetein AP et al (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961–972

    PubMed  Article  CAS  Google Scholar 

  52. Kappetein AP, Feldman TE, Mack MJ et al (2011) Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 32(17):2125–2134

    PubMed  Article  Google Scholar 

  53. Mohr FW, Morice MC, Kappetein AP et al (2013) Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 381(9867):629–638

    PubMed  Article  Google Scholar 

  54. Farkouh ME, Domanski M, Sleeper LA et al (2012) Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367(25):2375–2384

    PubMed  Article  CAS  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. H. Wienbergen und R. Hambrecht geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Affiliations

  1. Bremer Institut für Herz- und Kreislaufforschung, Klinikum Links der Weser, Herzzentrum Bremen, Senator-Weßling-Str. 1, 28277, Bremen, Deutschland

    H. Wienbergen & R. Hambrecht

Authors
  1. H. Wienbergen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Hambrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Wienbergen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wienbergen, H., Hambrecht, R. Differenzialtherapie der koronaren Herzkrankheit. Herz 39, 178–185 (2014). https://doi.org/10.1007/s00059-013-4049-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00059-013-4049-y

Schlüsselwörter

  • Koronare Herzerkrankung
  • Risikoprofil
  • Pharmakologische Therapie
  • Revaskularisation

Keywords

  • Coronary artery disease
  • Risk profile
  • Pharmacological therapy
  • Revascularisation therapy